COVID-19 variants potential factor in mixed Virios fibromyalgia resultsR&DVirios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia. Read more September 19, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpacefibromyalgia9-19-2022.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-09-19 11:00:392022-09-19 11:57:18COVID-19 variants potential factor in mixed Virios fibromyalgia results
